ArticleImmunotherapy2024

Cost-effectiveness analysis of immune checkpoint inhibitors as first-line therapy in advanced biliary tract cancer.

Ruizhe Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.